As number of COVID-19 cases in Russia crossed 500,000, the government has rolled out a drug to treat the novel coronavirus even though clinical trials are still underway.
The country's health ministry has approved the use of the anti-viral drug, registered under the name Avifavir, under a special accelerated process.
In a press release, the state financial backer said the drug has been delivered to some hospitals and clinics in the country.
The country's RDIF sovereign wealth fund has a 50 per cent share in a joint venture with the drug's manufacturer ChemRar.
There is currently no vaccine for COVID-19, with human trials of several existing antiviral drugs yet to show efficacy.
So far, the country has 502,436 positive cases and the death toll stands at 6,532.


Trump says US military strike killed leader of Venezuela's Tren de Aragua gang
US and Iran signal a peace deal is close
Qatar rejects media report on energy production decisions
Trump says Iran war deal close as Strait of Hormuz tensions linger
Victims' families mark Air India crash anniversary with prayers and tributes
Ebola outbreak spreads to crowded displacement camp in Congo
Fire breaks out at New Zealand's Wellington airport, disrupting flights
Ukraine and Russia trade overnight drone strikes, officials say
